<DOC>
	<DOCNO>NCT01996735</DOCNO>
	<brief_summary>Preclinical study show P2Y12 receptor antagonist ticagrelor increase extracellular concentration endogenous nucleoside adenosine inhibit cellular uptake adenosine via equilibrative nucleoside transporter ( ENT ) . This mechanism contribute beneficial effect side effect ( dyspnea ) ticagrelor patient acute myocardial infarction . In current research proposal , aim investigate whether ticagrelor increase adenosine receptor stimulation human vivo ENT inhibition .</brief_summary>
	<brief_title>Ticagrelor Adenosine</brief_title>
	<detailed_description />
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male sex Age 1840 year Healthy Written inform consent Smoking Hypertension ( Blood pressure &gt; 140 mmHg and/or &gt; 90 mmHg SBP/DBP ) Diabetes Mellitus ( fast glucose &gt; 7.0 mmol/L random &gt; 11.0 mmol/L ) History cardiovascular disease History chronic obstructive pulmonary disease ( COPD ) asthma Bleeding tendency Concomitant use medication Renal dysfunction ( MDRD &lt; 60 ml/min ) Liver enzyme abnormality ( ALAT &gt; twice upper limit normality ) Thrombocytopenia ( &lt; 150*109/ml ) Second/third degree AVblock electrocardiography</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Endothelial function</keyword>
	<keyword>Adenosine receptor stimulation</keyword>
</DOC>